Latest Topic for Clinical Effects of Tirzepatide as Dual GIP/GLP-1 Receptor Agonist

Treatment for Type 2 Diabetes (T2D) includes incretin hormones, such as glucagon-like peptide-1 (GLP-1) and also glucose-dependent insulinotropic polypeptide (GIP). As latest agent for T2D, twincretin of dual GIP and GLP-1 receptor agonist, tirzepatide has been studied for SURPASS clinical trials. Clinical efficacy of tirzepatide (5, 10, 15mg) has been reported, where HbA1c reduction showed 2.01%, 2.24% and 2.30%, respectively and weight reduction of tirzepatide was larger than semaglutide as 1.9kg, 3.6kg and 5.5kg, respectively. For comparative study of four-component major adverse cardiovascular event (MACE-4), tirzepatide showed Hazard Ratios (HRs) of 0.80 for MACE-4 and 0.90 for cardiovascular death.

© 2022 Bando H. this is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.